Pentostatin
- Generic Name
- Pentostatin
- Brand Names
- Nipent
- Drug Type
- Small Molecule
- Chemical Formula
- C11H16N4O4
- CAS Number
- 53910-25-1
- Unique Ingredient Identifier
- 395575MZO7
- Background
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
- Indication
For the treatment of hairy cell leukaemia refractory to alpha interferon.
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia (HCL), Mycosis Fungoides (MF), Sezary Syndrome, Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00096161
- Locations
- 🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸VA Puget Sound Health Care System, Seattle, Washington, United States
🇮🇹University of Torino, Torino, Italy
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
- Conditions
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 102
- Registration Number
- NCT00074282
- Locations
- 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸Marshfield Clinic at Saint Michael's Hospital, Stevens Point, Wisconsin, United States
🇺🇸Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 39
- Registration Number
- NCT00074035
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States
Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
- Conditions
- First Posted Date
- 2003-06-27
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00006968
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Pharmatech Oncology
- Registration Number
- NCT00026351
- Locations
- 🇺🇸
Cancer and Blood Institute of the Desert, Rancho Mirage, California, United States
🇺🇸Hematology Oncology Associates of Central New York, P.C., Syracuse, New York, United States
🇺🇸North Shore Hematology/Oncology Associates, P.C., East Setauket, New York, United States
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 6
- Registration Number
- NCT00057954
- Locations
- 🇺🇸
St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States
🇺🇸Tufts-NEMC Cancer Center, Boston, Massachusetts, United States
🇺🇸Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 17
- Registration Number
- NCT00045305
- Locations
- 🇺🇸
Jewish Hospital Cancer Center, Cincinnati, Ohio, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00003658
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- Hoag Memorial Hospital Presbyterian
- Registration Number
- NCT00049413
- Locations
- 🇺🇸
Hoag Cancer Center at Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.